- Home
- KIO vs ATXS Comparison
KIO vs ATXS Comparison
Compare KIO & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KIO
- ATXS
- Stock Information
- Founded
- KIO 2011
- ATXS 2008
- Country
- KIO United States
- ATXS United States
- Employees
- KIO 2400
- ATXS N/A
- Industry
- KIO Investment Managers
- ATXS Biotechnology: Pharmaceutical Preparations
- Sector
- KIO Finance
- ATXS Health Care
- Exchange
- KIO Nasdaq
- ATXS Nasdaq
- Market Cap
- KIO 499.0M
- ATXS 401.2M
- IPO Year
- KIO N/A
- ATXS 2015
- Fundamental
- Price
- KIO $12.19
- ATXS $5.99
- Analyst Decision
- KIO
- ATXS Strong Buy
- Analyst Count
- KIO 0
- ATXS 7
- Target Price
- KIO N/A
- ATXS $32.43
- AVG Volume (30 Days)
- KIO 136.5K
- ATXS 590.0K
- Earning Date
- KIO 01-01-0001
- ATXS 05-13-2025
- Dividend Yield
- KIO 10.82%
- ATXS N/A
- EPS Growth
- KIO N/A
- ATXS N/A
- EPS
- KIO N/A
- ATXS N/A
- Revenue
- KIO N/A
- ATXS N/A
- Revenue This Year
- KIO N/A
- ATXS N/A
- Revenue Next Year
- KIO N/A
- ATXS N/A
- P/E Ratio
- KIO N/A
- ATXS N/A
- Revenue Growth
- KIO N/A
- ATXS N/A
- 52 Week Low
- KIO $10.52
- ATXS $3.56
- 52 Week High
- KIO $13.59
- ATXS $12.92
- Technical
- Relative Strength Index (RSI)
- KIO 61.07
- ATXS 70.19
- Support Level
- KIO $12.16
- ATXS $3.83
- Resistance Level
- KIO $12.29
- ATXS $4.98
- Average True Range (ATR)
- KIO 0.09
- ATXS 0.44
- MACD
- KIO 0.01
- ATXS 0.20
- Stochastic Oscillator
- KIO 75.58
- ATXS 95.65
About KIO KKR Income Opportunities Fund
KKR Income Opportunities Fund operates as a closed-end registered management investment company. It seeks to generate a high level of current income, with a secondary objective of capital appreciation. The company invests in the portfolio of loans and fixed-income instruments of U.S. and non-U.S. issuers. The company will invest at least 80% of its Managed Assets in loans and fixed-income instruments or other instruments, including derivative instruments, with similar economic characteristics under normal market conditions.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.